NUI IOKA - Ua ʻōlelo ʻo Immunocore i ka Pōʻakahi e kūʻai aku ana i 3,733,333 mau ʻāpana i loko o kahi ʻaelike kālā hoʻopukapuka kālā pilikino (PIPE) i manaʻo ʻia e hōʻiliʻili i $140 miliona.
Ma lalo o ka ʻaelike, e kūʻai aku ʻo Immunocore i kāna mau waiwai maʻamau a me nā waiwai maʻamau ʻaʻole i koho balota no $37.50 no kēlā me kēia mahele. ʻO nā mea hoʻopukapuka kālā o ka hui e komo nei i ke kālā ʻo RTW Investments, Rock Springs Capital a me General Atlantic. Manaʻo ʻia e pau ka ʻaelike PIPE ma Iulai 20.
E hoʻohana ka ʻoihana i nā loaʻa kālā e hoʻolako kālā i kāna mau moho pipeline oncology a me nā maʻi lele, me ka hoʻomohala ʻana i kāna moho oncology alakaʻi, ʻo Kimmtrak (tebentafusp-tebn), e mālama i ka ʻili HLA-A * 02:01 maikaʻi a me ka uveal melanoma. ʻO ke kālā, me ka loaʻa kālā mai Kimmtrak, e manaʻo ʻia e hoʻolako kālā i nā hana a Immunocore a hiki i ka makahiki 2025.
I kēia makahiki, ua ʻāpono ʻia ʻo Kimmtrak no ka hoʻohana ʻana i nā poʻe maʻi me ka HLA-A * 02:01 positive unresectable a i ʻole metastatic uveal melanoma ma US, ʻEulopa a me UK, a me nā ʻāina ʻē aʻe. Ke hoʻomau nei ʻo Immunocore i ke aʻo ʻana i ka lāʻau lapaʻau ma kahi noiʻi Phase I / II ma ka HLA-A * 02:01-positive cutaneous melanoma.
Ke hoʻomohala nei ʻo Immunocore i ʻehā mau moho oncology ʻē aʻe, me ʻelua mau lāʻau lapaʻau receptor T-cell hou aʻe i nā hoʻokolohua Phase I/II i nā tumors paʻa kiʻekiʻe. Ke hoʻomohala ʻia nei kekahi o nā lāʻau lapaʻau no nā maʻi HLA-A * 02:01-positive a me MAGE-A4-positive, a ʻo nā mea ʻē aʻe e kuhikuhi ana i nā tumors HLA-A * 02:01 a me PRAME-positive. Loaʻa i ka hui ʻelua mau moho oncology i hōʻike ʻole ʻia i ka hoʻomohala preclinical.
Kulekele pilikino.nā ʻōlelo a me nā kūlana.Kuleana kope © 2022 GenomeWeb, kahi ʻāpana ʻoihana o Crain Communications.ua mālama ʻia nā kuleana āpau.